Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 5/20 | 0.49 |
| ▸ | BCR | P11274 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.46 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416495 | 0.86 | EGFR (0.57) | EGFRKDRPIP4K2APIK3CGRET | |
| SCHEMBL4414154 | 0.84 | ABL1 (0.71) | ABL1BCRTTBK1 | |
| SCHEMBL4412690 | 0.81 | MKNK1 (0.49) | ABL1BCREGFRTTBK1PIP4K2A | |
| SCHEMBL4421383 | 0.77 | RAB9A (0.57) | FLT3ABL1EGFRPIP4K2APIK3CG | |
| SCHEMBL4412925 | 0.75 | PIP4K2A (0.48) | EGFRKDRPIP4K2APIK3CG | |
| SCHEMBL4413342 | 0.75 | MAP4K4 (0.47) | PIP4K2APIK3CGAURKARPS6KB1AURKB | |
| SCHEMBL18696242 | 0.74 | ABL1 (0.59) | FLT3ABL1BCREGFRKDR | |
| SCHEMBL6454592 | 0.74 | MAPT (0.52) | KDR | |
| SCHEMBL4415185 | 0.74 | LMNA (0.58) | EGFRPIP4K2APIK3CG | |
| SCHEMBL4414264 | 0.74 | MAPT (0.57) | ABL1EGFRTTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658290-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-15 | — | — | EP | claimed |
| CN-100439365-C | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-12-03 | — | — | CN | claimed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | claimed |
| JP-2007504159-A | — | — | 2007-03-01 | — | — | JP | claimed |
| CN-1842529-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-10-04 | — | — | CN | claimed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | claimed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | claimed |
| EP-1658290-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-15 | — | — | EP | disclosed |
| CN-100439365-C | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-12-03 | — | — | CN | disclosed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| CN-1842529-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-10-04 | — | — | CN | disclosed |
| EP-1658290-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005039486-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | LCK, FYN, BMX | FLT3 102/4885ABL1 53/4885BCR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.